Lojong vs Recursion

Recursion is an enterprise techbio platform combining AI, automated wet labs, and over 50 petabytes of multi-omic data (phenomics, transcriptomics, proteomics, ADME, patient data) to accelerate drug discovery. It leverages NVIDIA BioHive-2 supercomputer for model training and integrates generative AI for molecule design. Key outputs include hit identification, target validation, and IND-enabling studies, with a pipeline of first-in-class candidates in oncology and rare diseases (e.g., REC-4881 in Phase 1b/2). In contrast, Lojong is a consumer mindfulness app offering hundreds of guided meditations in Portuguese, sleep stories, breathing exercises, yoga, and an emotional diary. It supports offline use and Apple Watch integration. While Recursion's output is clinical candidates and partnerships, Lojong's output is personal stress reduction and sleep improvement, with 70% of Premium users reporting reduced anxiety. Both use AI but in vastly different domains: Recursion's AI models biological systems; Lojong's AI curates personalized meditation programs.

Recursion operates on a contact-for-pricing model, tailored for pharmaceutical partnerships and large-scale collaborations. There is no public subscription — costs likely involve multi-million dollar commitments for platform access and co-development. Lojong uses a freemium model: basic features are free, with premium subscriptions unlocking full content. Pricing is designed for individual consumers, with typical app store rates (e.g., $9.99/month or annual discounts). There is no direct price comparison because the audiences and value propositions are entirely different: Recursion targets institutional R&D budgets, while Lojong targets personal wellness spending.